Aclaris Therapeutics, Inc. (ACRS)
(Delayed Data from NSDQ)
$1.88 USD
+0.15 (8.67%)
Updated Dec 13, 2019 03:56 PM ET
After-Market: $1.90 +0.02 (1.06%) 7:03 PM ET
3-Hold 3
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 2 3 4 5 S&P |
Strong Buy Buy Hold Sell Strong Sell 500 |
24.62% 17.69% 9.40% 5.11% 2.01% 10.65% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
F Value | D Growth | B Momentum | F VGM
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.
The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.
Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
Zacks News
Rigel Gets Positive CHMP Review for Thrombocytopenia Drug
by Zacks Equity Research
The CHMP advocates Rigel's (RIGL) marketing approval for Tavalisse to treat chronic immune thrombocytopenia in Europe.
RDHL ACRS JAZZ RIGL
medical
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ACRS
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Company News for Oct 17, 2019
by Zacks Equity Research
Companies In The News Are: GM, ACRS, MGM, AVD
MGM GM AVD ACRS
auto-tires-trucks medical
Aclaris Divests Rhofade to EPI Health for $55M, Shares Up
by Zacks Equity Research
Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.
AGN DERM RIGL ACRS
pharmaceuticals
Top Ranked Momentum Stocks to Buy for October 3rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 3rd.
ALLY ALGT ACRS ACA
medical travel-leisure
Top Ranked Momentum Stocks to Buy for September 27th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 27th.
ALLY AEP ACRS
medical
Aclaris Therapeutics, Inc. (ACRS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aclaris Therapeutics, Inc. (ACRS).
ACRS
medical
Aclaris (ACRS) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ACRS
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ACRS
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) rides high on both earnings and revenue beat in the second quarter of 2019. Moreover, Exparel drives year-over-year growth.
JNJ PCRX ACRS ZTS
earnings medical
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 6.49% and 1.65%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ACRS
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance
by Zacks Equity Research
Zoetis (ZTS) beats on earnings and sales in the second quarter and also raises its 2019 outlook.
GALT ZTS ACRS PTLA
pharmaceuticals
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ACRS
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Aclaris Therapeutics Enters Oversold Territory
by Zacks Equity Research
Aclaris Therapeutics has been on a bit of a cold streak lately.
ACRS
medical
What Makes Aclaris (ACRS) a New Buy Stock
by Zacks Equity Research
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ACRS
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Rigel Initiates Enrollment in Pivotal Blood Disorder Study
by Zacks Equity Research
Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.
AZN KALV RIGL ACRS
pharmaceuticals
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of -13.75% and -1.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
ACRS
earnings earnings-estimates earnings-outlook earnings-surprise energy industry-outlook zacks-consensus-estimate zacks-rank
Aclaris Therapeutics Enters Oversold Territory
by Zacks Equity Research
Aclaris Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
ACRS
medical
Aclaris Therapeutics (ACRS) Enters Oversold Territory
by Zacks Equity Research
Aclaris Therapeutics, Inc. (ACRS) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
ACRS
medical
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 15.20% and 3.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
ACRS
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Analysts Estimate Aclaris Therapeutics (ACRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ACRS
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Rigel (RIGL) Gets EMA Acceptance for Thrombocytopenia Drug
by Zacks Equity Research
The EMA validates Rigel Pharmaceuticals' (RIGL) marketing application for thrombocytopenia drug, Tavalisse.
UTHR RIGL ENDP ACRS
medical
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of -6.32% and 33.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
ACRS
Aclaris' Alopecia Candidate Gets Fast Track Designation
by Zacks Equity Research
The FDA grants fast track status to Aclaris' (ACRS) JAK-inhibitor, ATI-502, for the treatment of alopecia areata.
BLRX ACRX ACRS CLGN
Aclaris Stock Up on JAK Inhibitor's Encouraging Activity
by Zacks Equity Research
Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.
BLRX JAZZ ACRS CLGN